| Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor Q Liu, N Li, Y Yuan, H Lu, X Wu, C Zhou, M He, H Su, M Zhang, J Wang, ... Journal of medicinal chemistry 55 (1), 250-267, 2012 | 58 | 2012 |
| Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu … Y Yuan, SA Zaidi, O Elbegdorj, LCK Aschenbach, G Li, DL Stevens, ... Journal of medicinal chemistry 56 (22), 9156-9169, 2013 | 49 | 2013 |
| A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimer: binding affinity versus functional activities Y Yuan, CK Arnatt, N El-Hage, SM Dever, JC Jacob, DE Selley, ... Medchemcomm 4 (5), 847-851, 2013 | 42 | 2013 |
| Multistep parallel synthesis of substituted 5-aminobenzimidazoles in solution phase L Li, G Liu, Z Wang, Y Yuan, C Zhang, H Tian, X Wu, J Zhang Journal of Combinatorial Chemistry 6 (5), 811-821, 2004 | 40 | 2004 |
| Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5 Y Yuan, CK Arnatt, G Li, KM Haney, D Ding, JC Jacob, DE Selley, ... Organic & biomolecular chemistry 10 (13), 2633-2646, 2012 | 38 | 2012 |
| Characterization of 6α- and 6β-N-Heterocyclic Substituted Naltrexamine Derivatives as Novel Leads to Development of Mu Opioid Receptor Selective Antagonists Y Yuan, G Li, H He, DL Stevens, P Kozak, KL Scoggins, P Mitra, PM Gerk, ... ACS Chemical Neuroscience 2 (7), 346-351, 2011 | 38 | 2011 |
| Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization CK Arnatt, BA Falls, Y Yuan, TJ Raborg, RR Masvekar, N El-Hage, ... Bioorganic & medicinal chemistry 24 (22), 5969-5987, 2016 | 32 | 2016 |
| Synthesis of diverse benzo [1, 4] oxazin-3-one-based compounds using 1, 5-difluoro-2, 4-dinitrobenzene Y Yuan, G Liu, L Li, Z Wang, L Wang Journal of Combinatorial Chemistry 9 (1), 158-170, 2007 | 32 | 2007 |
| Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-[(4′-pyridyl) carboxamido] morphinan derivatives as peripheral selective μ … Y Yuan, O Elbegdorj, J Chen, SK Akubathini, F Zhang, DL Stevens, ... Journal of medicinal chemistry 55 (22), 10118-10129, 2012 | 28 | 2012 |
| Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6α-(isoquinoline-3′-carboxamido) morphinan analogues as opioid … Y Yuan, SA Zaidi, DL Stevens, KL Scoggins, PD Mosier, GE Kellogg, ... Bioorganic & medicinal chemistry 23 (8), 1701-1715, 2015 | 27 | 2015 |
| 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists Y Yuan, DL Stevens, A Braithwaite, KL Scoggins, EJ Bilsky, HI Akbarali, ... Bioorganic & medicinal chemistry letters 22 (14), 4731-4734, 2012 | 26 | 2012 |
| Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists P Mitra, J Venitz, Y Yuan, Y Zhang, PM Gerk Drug metabolism and disposition 39 (9), 1589-1596, 2011 | 24 | 2011 |
| Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats AA Altarifi, Y Yuan, Y Zhang, DE Selley, SS Negus Psychopharmacology 232, 815-824, 2015 | 21 | 2015 |
| Parallel Solution-Phase Synthesis of 4H-Benzo[1,4]thiazin-3-one and 1,1-Dioxo-1,4-dihydro-2H-1λ6-benzo[1,4]thiazin-3-one Derivatives from 1,5-Difluoro-2,4 … Z Wang, Y Yuan, Y Chen, G Sun, X Wu, S Zhang, C Han, G Wang, L Li, ... Journal of Combinatorial Chemistry 9 (4), 652-660, 2007 | 21 | 2007 |
| Structure selectivity relationship studies of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-[(4′-pyridyl) carboxamido] morphinan derivatives toward the development of … Y Yuan, O Elbegdorj, J Chen, SK Akubathini, IO Beletskaya, DE Selley, ... Bioorganic & medicinal chemistry letters 21 (18), 5625-5629, 2011 | 20 | 2011 |
| Structure activity relationship studies of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6α-(isoquinoline-3′-carboxamido) morphinan (NAQ) analogues as potent opioid … Y Yuan, O Elbegdorj, IO Beletskaya, DE Selley, Y Zhang Bioorganic & medicinal chemistry letters 23 (18), 5045-5048, 2013 | 19 | 2013 |
| 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-(4′-pyridylcarboxamido) morphinan (NAP) modulating the mu opioid receptor in a biased fashion Y Zhang, DA Williams, SA Zaidi, Y Yuan, A Braithwaite, EJ Bilsky, ... ACS chemical neuroscience 7 (3), 297-304, 2016 | 17 | 2016 |
| In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6α-(isoquinoline-3-carboxamido) morphinan (NAQ) as a low efficacy … S Obeng, Y Yuan, A Jali, DE Selley, Y Zhang European journal of pharmacology 827, 32-40, 2018 | 16 | 2018 |
| The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents KM Haney, F Zhang, CK Arnatt, Y Yuan, G Li, JL Ware, DA Gewirtz, ... Bioorganic & medicinal chemistry letters 21 (18), 5159-5163, 2011 | 16 | 2011 |
| Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions S Veiga, Y Yuan, X Li, NC Santos, G Liu, MARB Castanho Biochimica et Biophysica Acta (BBA)-General Subjects 1760 (1), 55-61, 2006 | 16 | 2006 |
